Ocugen Inc
Q2 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +3.54%.
Did OCGN Beat Earnings? Q2 2025 Results
Ocugen delivered a stronger-than-expected second quarter, beating Wall Street estimates on both the top and bottom lines as its modifier gene therapy pipeline continued to advance toward multiple regulatory milestones. The clinical-stage ophthalmology company posted a loss of $0.05 per share, ahead of the consensus estimate of $0.06 by 11.82%, while revenue of $1.37 million cleared the $350,000 analyst target by 292.29% and grew 20.3% year-over-year, driven by collaborative arrangement income that included a binding term sheet for exclusive Korean rights to OCU400 carrying upfront and milestone payments of up to $11.00 million. Operating discipline also helped, with total expenses falling to $15.17 million from $16.59 million a year earlier. The quarter's strategic headline was a proposed reverse merger of subsidiary OrthoCellix with Carisma Therapeutics, valuing OrthoCellix at roughly $135.00 million and designed to surface NeoCart's value while keeping capital focused on the gene therapy platform. Looking ahead, the company is targeting BLA filings for OCU400 in 2026, OCU410ST in 2027, and OCU410 in 2028, though cash of $27.32 million provides runway only into Q1 2026.
- Collaborative arrangement revenue of $1.4 million in Q2 2025
- Lower R&D expenses ($8.4M vs $8.9M) and G&A expenses ($6.8M vs $7.7M) year-over-year
- Narrower net loss per share of -$0.05 vs -$0.06 in Q2 2024
“While our modifier gene therapy clinical trials advance—now with two in late-stage—we are securing strategic partnerships and evolving the business to support three successful Biologics License Application (BLA) filings over the next three years.”
Ocugen CEO, on the earnings call
Forward Guidance & Outlook
Ocugen targets three BLA filings over the next three years: OCU400 BLA/MAA submissions in 2026 for retinitis pigmentosa, OCU410ST BLA submission by 2027 for Stargardt disease, and OCU410 BLA submission by 2028 for geographic atrophy. The company expects to complete OCU400 manufacturing process validation this year and complete the OCU200 Phase 1 trial in the second half of 2025. NIAID intends to initiate the Phase 1 clinical trial for OCU500 in Q3 2025. The company's cash runway extends into Q1 2026. The OrthoCellix reverse merger with Carisma Therapeutics is intended to unlock value from NeoCart while enabling focus of capital on the modifier gene therapy platform. The company is pursuing additional regional partnership opportunities for OCU400 and all gene therapy candidates.
OCGN YoY Financials
OCGN Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.